Theraclion SA (ALTHE) AI Stock Analysis

• Market Cap: $31.51M
• Dividend Yield: N/A
• Average Volume (3M): 271.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: -54.44%
• EPS Growth: -51.95%
• Country: FR
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 47,057,285
• 10 Day Avg. Volume: 137,482
• 30 Day Avg. Volume: 271,421
• PEG Ratio: -0.05
• Price to Book (P/B): -133.83K
• Price to Sales (P/S): 18.38
• P/FCF Ratio: -5.06
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 15.01
• Enterprise Value/Gross Profit: -1.74
• Enterprise Value/Ebitda: -2.20
• 1Y Price Target: $0.50
• Price Target Upside: -27.09% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: €0.50 ▼(-26.47% Downside)

Theraclion SA's overall stock score is primarily impacted by its poor financial performance, which is the most significant factor. The technical analysis also indicates a bearish trend, contributing to the low score. The valuation is unattractive due to negative earnings and lack of dividends. The absence of earnings call data and corporate events means these components do not influence the score.

Theraclion SA Business Overview & Revenue Model

Company Description

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.

How the Company Makes Money

Theraclion generates revenue primarily through the sale of its Echopulse systems and the associated consumables required for treatment procedures. The company also earns income from service contracts, maintenance, and training for healthcare professionals using their technology. Additionally, Theraclion partners with hospitals and medical centers to facilitate the adoption of its technology, which can lead to further revenue opportunities through collaborative clinical programs and research initiatives. These partnerships enhance the company’s market presence and drive demand for its products, contributing significantly to its earnings.

Theraclion SA Financial Statement Overview

Summary

Theraclion SA is facing significant financial challenges. The income statement shows severe profitability issues with declining revenues and negative margins. The balance sheet reveals a critical financial position with negative equity and high leverage, posing solvency risks. While there is some improvement in free cash flow, the overall cash flow situation remains concerning.

Income Statement

Theraclion SA's income statement reveals significant challenges. The company has experienced a sharp decline in revenue with a negative growth rate of -75.43% in the latest year. Margins are deeply negative across the board, with a gross profit margin of -8.65% and a net profit margin of -6.94%, indicating substantial losses relative to revenue. The EBIT and EBITDA margins are also negative, reflecting ongoing operational difficulties. Overall, the income statement suggests a struggling financial performance with no immediate signs of profitability.

Balance Sheet

The balance sheet of Theraclion SA highlights severe financial instability. The company has a negative stockholders' equity, leading to an extremely high and negative debt-to-equity ratio of -11369.81, indicating potential solvency issues. The return on equity is alarmingly high at 50500%, but this is due to the negative equity base rather than strong performance. The equity ratio is not calculable due to negative equity, further emphasizing the company's precarious financial position.

Cash Flow

Theraclion SA's cash flow statement shows some positive aspects, despite overall negative cash flows. The free cash flow growth rate is positive at 93.77%, suggesting some improvement in cash generation. However, both operating and free cash flows remain negative, and the operating cash flow to net income ratio is -0.78, indicating that the company is not generating sufficient cash from its operations to cover its net losses. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally better than net income, but overall cash flow health remains weak.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	830.00K	1.82M	1.24M	1.48M	744.00K
Gross Profit	-7.18M	-1.08M	-3.05M	-4.54M	-3.81M
EBITDA	-6.96M	-4.49M	-5.74M	-4.40M	-4.15M
Net Income	-5.76M	-3.68M	-4.96M	-3.76M	-3.90M
Balance Sheet
Total Assets	11.47M	18.66M	13.94M	11.83M	10.55M
Cash, Cash Equivalents and Short-Term Investments	4.17M	7.82M	2.52M	2.49M	2.35M
Total Debt	1.30M	1.95M	2.51M	2.39M	10.61M
Total Liabilities	11.47M	13.01M	13.40M	13.10M	13.78M
Stockholders Equity	-114.00	5.65M	544.87K	-1.27M	-3.24M
Cash Flow
Free Cash Flow	-3.01M	-2.60M	-5.59M	-4.03M	-3.45M
Operating Cash Flow	-2.91M	-2.48M	-5.27M	-3.88M	-3.32M
Investing Cash Flow	-188.00K	-213.52K	-739.63K	-524.46K	-192.55K
Financing Cash Flow	-545.00K	7.99M	6.03M	4.56M	4.41M

Theraclion SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.68
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHE, the sentiment is Neutral. The current price of 0.68 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.72, and above the 200-day MA of 0.38, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.09 is Neutral, neither overbought nor oversold. The STOCH value of 8.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALTHE.

Theraclion SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALTHE	41 Neutral	$31.51M	―	-199.44%	―	-54.44%	-51.95%